To explore the potential effect of PPRPS on immunotherapy for bladder cancer, we obtained data from the IMvigor210 cohort to evaluate the efficacy of atezolizumab, an anti-PD-L1 monoclonal antibody, in patients with metastatic urothelial cancer. Here, CD274 is linked to urinary bladder carcinoma.